Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc.

Pan-RAS分子胶ERAS-0015和Pan-KRAS抑制剂ERAS-4001是有效的口服抑制剂，在RASm实体瘤管道优先化和劳动力重组方面具有潜在的同类最佳概况，使人们更加关注针对最高未满足需求和最高成功概率的计划，同时定价1.6亿美元的股权，提供Erasca于2024年5月17日星期五上午8:30在2024年5月16日圣地亚哥举行电话会议和网络广播（环球新闻网）--Erasca，Inc。

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue (ERAS-0015) and a potential first-in-class pan-KRAS inhibitor (ERAS-4001)—and provided a pipeline update.

（纳斯达克：ERAS），一家临床阶段精准肿瘤学公司，专注于为RAS/MAPK途径驱动的癌症患者发现，开发和商业化治疗，今天宣布，它已经为两个临床前RAS项目签订了独家许可协议-潜在的一流泛RAS分子胶（ERAS-0015）和潜在的一流泛KRAS抑制剂（ERAS-4001）-并提供了管道更新。

ERAS-0015 and ERAS-4001 are highly potent, orally bioavailable molecules with complementary RAS inhibitory mechanisms that have the potential to address unmet needs in nearly 2.7 million patients who are diagnosed annually globally with RAS-mutant (RASm) tumors, of which over 2.2 million patients are diagnosed with KRAS-mutant (KRASm) tumors.

ERAS-0015和ERAS-4001是具有互补RAS抑制机制的高效口服生物可利用分子，有可能解决全球每年诊断为RAS突变（RASm）肿瘤的近270万患者的未满足需求，其中超过220万患者被诊断为KRAS突变（KRASm）肿瘤。

As separately announced, Erasca has priced an equity offering of $160 million with a high quality group of new and existing healthcare-focused investors. “We’re thrilled to add ERAS-0015 and ERAS-4001 to our pipeline. Successful in-licensing of this RAS-targeting franchise with such broad potential to address unmet needs in patients helps advance our mission to erase cancer and is consistent with our focus on eradicating RAS/MAPK pathway-driven tumors,” said Jonathan E.

正如另外宣布的那样，Erasca已与一批新的和现有的以医疗保健为重点的高质量投资者合作，为1.6亿美元的股票发行定价。乔纳森·E说：“我们很高兴将ERAS-0015和ERAS-4001添加到我们的渠道中。成功获得这项针对RAS的特许经营权，具有解决患者未满足需求的广泛潜力，有助于推进我们消除癌症的使命，这与我们根除RAS/MAPK途径驱动的肿瘤的重点是一致的。”。

Lim, M.D., Erasca’s chairman, CEO, and co-founde.

医学博士Lim是Erasca的董事长、首席执行官和联合创始人。